Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03720717 · ClinicalTrials.gov registry record · Phase 4
Baclofen as a Perioperative Analgesic Adjuvant
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
NCT03720717 is a Phase 4 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 34 participants.
The verdict
NCT03720717, a Phase 4 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a single, oral dose of baclofen alters postoperative opioid requirements.
Interventions
- OTHER Placebo
- DRUG Baclofen 10mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2020-10-27 |
| Est. Completion | 2022-10-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03720717
The ClinicalTrials.gov registry entry for NCT03720717 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03720717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03720717 about?
NCT03720717 is a clinical study titled "Baclofen as a Perioperative Analgesic Adjuvant". The purpose of this study is to determine whether a single, oral dose of baclofen alters postoperative opioid requirements.
What is the current status of trial NCT03720717?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2020-10-27. Estimated completion is 2022-10-28.
What interventions are being tested in trial NCT03720717?
The interventions under investigation include: Placebo (OTHER), Baclofen 10mg (DRUG).
Who is sponsoring clinical trial NCT03720717?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.